Phase 2 Study of ALN-AGT01 RVR Given as a Single Dose in Adults With Mild to Moderate Hypertension Previously Treated With Zilebesiran

What this Trial Is About

Researchers are investigating the effects of ALN-AGT01 RVR in adults with mild to moderate hypertension who have previously been treated with zilebesiran. The study aims to evaluate how well ALN-AGT01 RVR works, how it affects the body pharmacodynamics, and its safety. This is a Phase 2 study involving participants aged 18 to 75 years who have specific blood pressure ranges and treatment histories. The trial has two parts Part A focuses on a single dose of ALN-AGT01 RVR in adults with mild to moderate hypertension, while Part B also involves a single dose but includes participants who have discontinued most antihypertensive medications except certain types. Participants receive a single dose of zilebesiran followed by either ALN-AGT01 RVR or placebo, both administered under the skin subcutaneously. Participants will be monitored for changes in blood pressure and serum angiotensinogen levels at several time points, including up to seven days after dosing. Safety is assessed by tracking adverse events for up to 10 months. The study includes blood pressure measurements and laboratory tests to evaluate kidney function and potassium levels. The total duration of participation varies, with primary outcomes measured within the first week and longer safety follow-up extending several months.

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran